Cardiovascular Diabetology

Article	Citations
Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin	263
Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome	157
Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations	153
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin	147
Triglyceride–glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies	143
Cardiovascular morbidity, diabetes and cancer risk among children and adolescents with severe obesity	131
Associations between abdominal obesity indices and diabetic complications: Chinese visceral adiposity index and neck circumference	127
Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19	110
Glycemic variability: adverse clinical outcomes and how to improve it?	108
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries	104
Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC)	102
SGLT2i: beyond the glucose-lowering effect	102
Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study	100
Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome	99
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs	97
Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort	95
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial	95
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease	91
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis	90
The impact of triglyceride-glucose index on incident cardiovascular events during 16 years of follow-up: Tehran Lipid and Glucose Study	89
Triglyceride–glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort	86
Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury	86
Positive association between triglyceride glucose index and arterial stiffness in hypertensive patients: the China H-type Hypertension Registry Study	86
Triglyceride glucose index is an independent predictor for the progression of coronary artery calcification in the absence of heavy coronary artery calcification at baseline	84
SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials	83

Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China	81
Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II)	80
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes	77
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction	77
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry	76
Stronger association of triglyceride glucose index than the HOMA-IR with arterial stiffness in patients with type 2 diabetes: a real-world single-centre study	76
Association between triglyceride-glucose index and risk of arterial stiffness: a cohort study	74
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management	73
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analy	72
Triglyceride-glucose index and the risk of stroke and its subtypes in the general population: an 11-year follow-up	71
Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study	71
Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis	71
Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications	67
Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19	67
Change in triglyceride-glucose index predicts the risk of cardiovascular disease in the general population: a prospective cohort study	66
Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte	66
Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA	65
Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs	65
Triglyceride glucose index for the detection of asymptomatic coronary artery stenosis in patients with type 2 diabetes	62
Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach	62
Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system	61
Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population	61
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs	60
Empagliflozin prevents doxorubicin-induced myocardial dysfunction	60
Direct cardiac effects of SGLT2 inhibitors	60
Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins	58
Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes	58
A high triglyceride glucose index is more closely associated with hypertension than lipid or glycemic parameters in elderly individuals: a cross-sectional survey from the Reaction Study	56
The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study	56
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy	54
Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents	53
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs	53
Global trend of diabetes mortality attributed to vascular complications, 2000–2016	52
MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics	52
Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF	50
Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study	50
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk	49
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug	49
Variability of risk factors and diabetes complications	48
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis	47
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management	46
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study	43
Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis	43
Correlation of physical and cognitive impairment in diabetic and hypertensive frail older adults	43
Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA	43
High triglyceride-glucose index is associated with subclinical cerebral small vessel disease in a healthy population: a cross-sectional study	43
Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report	42
The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes	42
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial	42
Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart failure	42

Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications	41
Gender difference in the association between TyG index and subclinical atherosclerosis: results from the I-Lan Longitudinal Aging Study	41
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study	40
Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study	40
Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus	40
Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular	39
Diabetes and restenosis	39
The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors	39
Discordance between the triglyceride glucose index and fasting plasma glucose or HbA1C in patients with acute coronary syndrome undergoing percutaneous coronary intervention predicts cardiovascular ev	39
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management	38
Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes	38
Predictive effect of triglyceride‑glucose index on clinical events in patients with type 2 diabetes mellitus and acute myocardial infarction: results from an observational cohort study in China	38
Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes	38
Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study	38
Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study	38
Issues for the management of people with diabetes and COVID-19 in ICU	38
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 tr	38
Arterial stiffness is an independent predictor for risk of mortality in patients with type 2 diabetes mellitus: the REBOUND study	37
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention	37
Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis	37
Association between the triglyceride–glucose index and severity of coronary artery disease	36
Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling	36
Quantitative assessment of coronary plaque volume change related to triglyceride glucose index: The Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADI	36
Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients	36
Evaluation of the long-term prognostic ability of triglyceride-glucose index for elderly acute coronary syndrome patients: a cohort study	36
TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients	36
Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death	36
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis	36
Triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China	36
Triglyceride-glucose index and common carotid artery intima-media thickness in patients with ischemic stroke	35
Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis	34
Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults	34
MicroRNAs and obesity-induced endothelial dysfunction: key paradigms in molecular therapy	34
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect	33
Predictive value of the stress hyperglycemia ratio in patients with acute ST-segment elevation myocardial infarction: insights from a multi-center observational study	33
The triglyceride-glucose index predicts ischemic heart disease risk in Koreans: a prospective study using National Health Insurance Service data	33
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the	33
Association between the Mediterranean lifestyle, metabolic syndrome and mortality: a whole-country cohort in Spain	33
Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies	32
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system	32
Triglyceride-glucose index variability and incident cardiovascular disease: a prospective cohort study	32
Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance	31
Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke	31
Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study	30
MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes	30
Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry	29
Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study	29
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure	29
Comparison of various insulin resistance surrogates on prognostic prediction and stratification following percutaneous coronary intervention in patients with and without type 2 diabetes mellitus	29
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression	29
Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)	29
SGLT2 inhibitors and lower limb complications: an updated meta‐analysis	29
Left atrial strain and diastolic function abnormalities in obese and type 2 diabetic adolescents and young adults	29
Triglyceride-glucose index trajectory and stroke incidence in patients with hypertension: a prospective cohort study	29
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND	29
Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes	28
Association of visceral adiposity index with incident nephropathy and retinopathy: a cohort study in the diabetic population	28
Association between physical activity level and cardiovascular risk factors in adolescents living with type 1 diabetes mellitus: a cross-sectional study	28
Relationship of cumulative exposure to the triglyceride-glucose index with ischemic stroke: a 9-year prospective study in the Kailuan cohort	28
Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study	28
Associations between continuous glucose monitoring-derived metrics and arterial stiffness in Japanese patients with type 2 diabetes	28
Association of the atherogenic index of plasma with cardiovascular risk beyond the traditional risk factors: a nationwide population-based cohort study	28
Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system	27
PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis	27
High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort	27
Diabetes as a risk factor for incident peripheral arterial disease in women compared to men: a systematic review and meta-analysis	27
Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study	27
Insulin directly stimulates mitochondrial glucose oxidation in the heart	27
The association of hepatic steatosis and fibrosis with heart failure and mortality	27
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study	27
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus	27
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence	27
Triglyceride-glucose index in the development of peripheral artery disease: findings from the Atherosclerosis Risk in Communities (ARIC) Study	27
Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data	27
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes	27
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure	27
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study	26
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice	26
Reappraisal on pharmacological and mechanical treatments of heart failure	26
Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study	26

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (P	26
The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort stu	26
Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants	26
Triglyceride-glucose index trajectory and arterial stiffness: results from Hanzhong Adolescent Hypertension Cohort Study	26
Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus	26
Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes	26
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial	26
Association of fasting glucose with lifetime risk of incident heart failure: the Lifetime Risk Pooling Project	26
Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study	26
Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis	26
Triglyceride-glucose index and the risk of heart failure: Evidence from two large cohorts and a mendelian randomization analysis	26
Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study	25
Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational coho	25
HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target	25
Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a cross-sectional study	25
Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials	25
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes	25
Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients	25
Prognostic significance of diabetes mellitus in patients with atrial fibrillation	25
Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes	25
Impact of glycemic control on the association of endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus	24
Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial	24
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study	24
Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study	24
Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes	24
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial	24
SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis	24
Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease	24
Neuregulin-4 attenuates diabetic cardiomyopathy by regulating autophagy via the AMPK/mTOR signalling pathway	24
Glucose variability and the risks of stroke, myocardial infarction, and all-cause mortality in individuals with diabetes: retrospective cohort study	24
Atherogenic index of plasma for non-diabetic, coronary artery disease patients after percutaneous coronary intervention: a prospective study of the long-term outcomes in China	24
Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study	23
Impact of combined training with different exercise intensities on inflammatory and lipid markers in type 2 diabetes: a secondary analysis from a 1-year randomized controlled trial	23
Association between triglyceride glucose index and carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China	23
Sex differences in the association of prediabetes and type 2 diabetes with microvascular complications and function: The Maastricht Study	23
Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney	23
Trends in diabetes-related complications in Hong Kong, 2001–2016: a retrospective cohort study	23
Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study	23
A molecular signature for the metabolic syndrome by urine metabolomics	22
Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics	22
High triglyceride-glucose index in young adulthood is associated with incident cardiovascular disease and mortality in later life: insight from the CARDIA study	22
The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus	22
Association of healthy lifestyle including a healthy sleep pattern with incident type 2 diabetes mellitus among individuals with hypertension	22
CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease	22
Landscape of cardiometabolic risk factors in Chinese population: a narrative review	22
Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study	22
Sex-specific differences in left ventricular mass and myocardial energetic efficiency in non-diabetic, pre-diabetic and newly diagnosed type 2 diabetic subjects	22
Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort	22
Association of stress induced hyperglycemia with angiographic findings and clinical outcomes in patients with ST-elevation myocardial infarction	21
Visit-to-visit HbA1c variability is associated with in-stent restenosis in patients with type 2 diabetes after percutaneous coronary intervention	21
Cumulative burden of metabolic syndrome and its components on the risk of atrial fibrillation: a nationwide population-based study	21
Triglyceride-glucose index linked to all-cause mortality in critically ill patients: a cohort of 3026 patients	21
Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis	21
Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach	21
Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study	21
Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study	21
Association between abdominal obesity indices and risk of cardiovascular events in Chinese populations with type 2 diabetes: a prospective cohort study	21
Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases	20
Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary tr	20
Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes	20
Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus	20
Change in glucose intolerance status and risk of incident cardiovascular disease: Tehran Lipid and Glucose Study	20
Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events	20
Association of sleep disturbance with risk of cardiovascular disease and all-cause mortality in patients with new-onset type 2 diabetes: data from the Korean NHIS-HEALS	19
Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis	19
Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis	19
Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database	19
Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inh	19
Report from the 5th cardiovascular outcome trial (CVOT) summit	19
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial	19
Metabolic syndrome and the plasma proteome: from association to causation	19
Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials	19
Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation	19
Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease	19
Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation	19
High pericoronary adipose tissue attenuation on computed tomography angiography predicts cardiovascular events in patients with type 2 diabetes mellitus: post-hoc analysis from a prospective cohort st	19
Epicardial adipose tissue volume and coronary calcification among people living with diabetes: a cross-sectional study	19
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLE	19
Sortilin levels correlate with major cardiovascular events of diabetic patients with peripheral artery disease following revascularization: a prospective study	19
Correlation between the triglyceride-to-high-density lipoprotein cholesterol ratio and other unconventional lipid parameters with the risk of prediabetes and Type 2 diabetes in patients with coronary	19
Association between triglyceride glucose-body mass index and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a retrospective study	19
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report	19
Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes	19
Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease	18
Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium	18
Associations of (pre)diabetes with right ventricular and atrial structure and function: the Maastricht Study	18
Exposure-weighted scoring for metabolic syndrome and the risk of myocardial infarction and stroke: a nationwide population-based study	18
Impact of diabetes mellitus on left ventricular longitudinal function of patients with non-ischemic dilated cardiomyopathy	18
Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness	18
Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure	18
Impact of red cell distribution width and red cell distribution width/albumin ratio on all-cause mortality in patients with type 2 diabetes and foot ulcers: a retrospective cohort study	18
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy	18
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms	18
Plasma metabolomic profiling in subclinical atherosclerosis: the Diabetes Heart Study	18
Pericardial fat and its influence on cardiac diastolic function	18